Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
134.94
-1.04 (-0.76%)
At close: Apr 28, 2026, 4:00 PM EDT
134.92
-0.02 (-0.01%)
After-hours: Apr 28, 2026, 7:13 PM EDT
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$364,437
Profits / Employee
-$767,293
Market Cap
29.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Revolution Medicines | 883 |
INSM News
- 5 days ago - Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 - PRNewsWire
- 21 days ago - Insmed discontinues development of skin condition drug after mid-stage study miss - Reuters
- 21 days ago - Insmed Provides Clinical Update on Phase 2b CEDAR Study - PRNewsWire
- 5 weeks ago - Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
- 5 weeks ago - Insmed Transcript: Study result - Transcripts
- 5 weeks ago - Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease - PRNewsWire
- 7 weeks ago - Insmed Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire